Literature DB >> 19447046

IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity.

Jinguo Wang1, Linda S Wicker, Pere Santamaria.   

Abstract

Type 1 diabetes (T1D) is an organ-specific autoimmune disease featured by destruction of the insulin producing beta-cells of the pancreas by autoreactive T-lymphocytes. Putative environmental triggers conspire with a constellation of genetic elements scattered throughout the genome to elicit a multifactorial autoimmune response involving virtually every cell type of the immune system against pancreatic beta-cells. Recent highly powered genome-wide association studies have confirmed and identified fifteen chromosomal regions harboring several candidate T1D-associated gene loci. Here, we summarize what we know about the genetics of T1D with an emphasis on the contributions of mouse Il2 and human IL2RA polymorphisms and the IL-2-IL-2R pathway to autoimmunity and, more specifically, Treg development and function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447046     DOI: 10.1016/j.smim.2009.04.004

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  21 in total

1.  An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Authors:  Rodolfo José Chaparro; Teresa P Dilorenzo
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

Review 2.  Regulatory T cells as therapeutic targets in rheumatoid arthritis.

Authors:  Jonathan H Esensten; David Wofsy; Jeffrey A Bluestone
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

3.  Interleukin-2-mediated inhibition of dendritic cell development correlates with decreased CD135 expression and increased monocyte/macrophage precursors.

Authors:  Alan D Guerrero; Matthew B Dong; Yongge Zhao; Annie Lau-Kilby; Kristin V Tarbell
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

Review 4.  T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells.

Authors:  Guoyan Cheng; Aixin Yu; Thomas R Malek
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

Review 5.  Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?

Authors:  Anabelle Visperas; Dario A A Vignali
Journal:  J Immunol       Date:  2016-11-15       Impact factor: 5.422

6.  Interleukin-2 inhibits FMS-like tyrosine kinase 3 receptor ligand (flt3L)-dependent development and function of conventional and plasmacytoid dendritic cells.

Authors:  Annie W Lau-Kilby; Cosima C Kretz; Susanne Pechhold; Jeffrey D Price; Stephanie Dorta; Haydee Ramos; Giorgio Trinchieri; Kristin V Tarbell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

7.  The adenosine A₂A receptor - myocardial protectant and coronary target in endotoxemia.

Authors:  Melissa E Reichelt; Kevin J Ashton; Xing Lin Tan; S Jamal Mustafa; Catherine Ledent; Lea M D Delbridge; Polly A Hofmann; John P Headrick; R Ray Morrison
Journal:  Int J Cardiol       Date:  2011-12-20       Impact factor: 4.164

8.  Genetic interactions among Idd3, Idd5.1, Idd5.2, and Idd5.3 protective loci in the nonobese diabetic mouse model of type 1 diabetes.

Authors:  Xiaotian Lin; Emma E Hamilton-Williams; Daniel B Rainbow; Kara M Hunter; Yang D Dai; Jocelyn Cheung; Laurence B Peterson; Linda S Wicker; Linda A Sherman
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

9.  Effect of interleukin-2 level and genetic variants on coronary artery disease.

Authors:  Ru Ding; Wenwu Gao; David H Ostrodci; Zhiqing He; Yuanlin Song; Lan Ma; Chun Liang; Zonggui Wu
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

10.  Induction of autoimmune diabetes in non-obese diabetic mice requires interleukin-21-dependent activation of autoreactive CD8⁺ T cells.

Authors:  X-L Chen; D Bobbala; G M Rodriguez; M Mayhue; Y-G Chen; S Ilangumaran; S Ramanathan
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.